Sagent Pharmaceuticals Announces the Launch of Carboplatin Injection

SCHAUMBURG, Ill., Nov. 4, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Carboplatin Injection, an antineoplastic agent, in four preservative-free vial presentations. According to IMS, for the 12 months ending September 2013, the US market for Carboplatin Injection approximated $30 million. As with all products in Sagent's portfolio, Carboplatin features Sagent's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.

"We are particularly proud of the launch of Carboplatin, the first product manufactured at our SCP facility," said Jeffrey M. Yordon, Chief Executive Officer and Chairman of the Board of Sagent. "SCP is a 300,000 square foot FDA and cGMP compliant sterile manufacturing facility located in Chengdu, China that utilizes state-of-the art isolator technology. The facility was designed initially to support the supply of chronically short oncology products. Carboplatin is the first in a long list of products that we look forward to supplying from this facility,"

About Carboplatin Injection

Carboplatin Injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. Carboplatin Injection is also indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.

The package insert, available at, contains the indications, complete side effect profile, and prescribing information.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.

CONTACT: INVESTOR CONTACT: Jonathon Singer, Sagent 847-908-1605Source:Sagent Pharmaceuticals, Inc.